Limin Guan has 17 years of experience in the pharmaceutical industry, beginning with technical roles in drug substance process development within a pilot plant setting. Over the past 10 years, he has honed his expertise in clinical supply chain management, starting his journey at Novartis. His professional background includes integrating global supply chain experience across the US, EU, APAC, and beyond, through roles at Novartis, Zailab, Beigene, and Takeda, with a particular focus on the Asia-Pacific region. Currently, Limin provides leadership and strategic direction for Clinical Supply Chain activities in China and the APAC region. His responsibilities include overseeing outsourced operations, serving as the Global Clinical Supply Chain representative to local functions, and advancing capabilities in project planning and execution.

管利民在制药行业拥有17年的经验，最初从事药物原料工艺开发的技术工作，主要集中在中试车间领域。在过去的10年里，他在临床供应链管理方面积累了丰富的经验，并从诺华开始了这一领域的职业旅程。他的职业背景包括在诺华、再鼎、百济和武田公司等担任职务，整合了在美国、欧洲、亚太地区及其他地区的全球供应链经验，尤其专注于亚太区域。目前，他负责领导和制定中国及亚太地区临床供应链活动的战略方向。他的职责涵盖监督外包业务，作为武田全球临床供应链与当地职能部门之间的代表，并推动项目规划与执行能力的提升。

礼新医药临床运营副总裁。曾在精鼎、方恩等CRO公司任职并负责方恩临床运营工作，此后在罗氏以及珐博进、华领、康宁杰瑞等Biotech企业担任临床运营部门负责人，负责多项国际国内研究，并助力多项1.1类新药成功获批。

Paul Kong, leads Clinical Operation team within LaNova since Apr, 2021. He has more than 10 years experiences in CRO, such as Parexel and FMD, and then taking the leading role from various biotechs and big pharm, Roche, FibroGen, Hua Medicine and Alphamab in clinical operation team; and he has major contributions for lots of first in class production registration.

秦飞拥有超过15年的医疗行业经验，PMI认证项目管理专家，专注于临床研究领域项目管理，临床路径规划，临床运营及创新智能化解决方案。她曾就职于罗氏制药、巴德医疗（碧迪医疗）、BI(勃林格殷格翰)以及史赛克医疗等世界知名医疗企业，曾担任中国区临床事务负责人，积累了丰富的药物及医疗器械GCP的知识和实践经验，在创新医疗器械、优化临床数据的应用，实施项目管理风险管控等方面尤其热衷。现兼任中国残疾人康复协会-医疗器械临床试验质量管理专业委员会委员，DIA真实世界研究工作组成员。

Megan Qin has over 15 years of experience in the healthcare industry and is a PMI-certified Project Management Professional specializing in clinical research project management, clinical pathway planning, clinical operations, and innovative intelligent solutions. She has held positions at world-renowned healthcare companies including Roche Medical, Bard Medical (BD), BI (Boehringer Ingelheim), and Stryker Neurovascular, where she served as the Head of Clinical Affairs for China, accumulating extensive knowledge and hands-on experience in GCP (Good Clinical Practice) for drugs and medical devices. She is particularly passionate about innovative medical devices, optimizing clinical data applications, and implementing project management risk controls.
Currently, she also holds roles as Committee Member of Medical Device Clinical Trial Quality Management Committee-China Association of Rehabilitation of Disabled Persons and Working Group Member of DIA Real-World Evidence Research Group.

李四维博士，达歌生物药代动力学总监。2008年毕业于南京大学生物技术专业本科，2014年获美国辛辛那提大学化学博士学位。随后在美国密西根大学药学院从事博士后研究，并获斯坦福大学数据科学职业认证。李博士拥有10余年的药物研发经验，曾先后担任AI制药公司AI药理总监、百济神州高级主任研究员及美国硅谷精准医学公司研究科学家。同时，他还是爱思唯尔《Food Chemistry》期刊的杰出审稿人。李博士的研究方向聚焦于小分子非临床药代动力学研究；模型引导的药物研发(MIDD): PKPD模型和AI模型在药物研发中开发和应用；生物分析技术开发与应用。他还在AI赋能蛋白质组学及代谢组学研究方向拥有多年实践经验。曾参与10余个新药研发项目，并主导参与多个中美IND申报相关的非临床药代动力学研究工作。迄今在国际知名期刊发表论文20余篇及申请专利1项。

Dr. Siwei Li, Director of DMPK at Degron Therapeutics. Dr. Li earned his B.S. in Biotechnology from Nanjing University in 2008 and received his Ph.D. in Chemistry from the University of Cincinnati (USA) in 2014. Then he served as postdoctoral research fellow at the University of Michigan College of Pharmacy and also obtained a professional certificate in Data Science from Stanford University. With over 10 years of experience in drug discovery and development, Dr. Li has held key positions including Director of AI Pharmacology at an AI Drug Discovery biotech company, Senior Principal Investigator at BeiGene, and Research Scientist at a Silicon Valley precision medicine company. He is also recognized as an Elsevier Outstanding Reviewer for Food Chemistry journal. His research focuses on small molecule non-clinical pharmacokinetics, Model-Informed Drug Discovery (MIDD): PKPD and AI model development and application in drug discovery and development, Bioanalytical technology development and application, AI-driven proteomics and metabolomics research. Dr. Li has contributed to 10+ drug discovery programs and led/participated in non-clinical PK studies supporting multiple China-US IND filings. To date, he has published over 20 papers in internationally renowned journals and filed 1 patent application.

臧文升在临床运营行业已深耕16年。曾就职于于ICON、强生、先声药业，2019年加入信达生物。承担过多项药物（小分子化药、单抗、双抗、多肽等）的临床开发的全阶段的工作，并已有多个产品成功获批上市。在新药临床开发方面积累了丰富的经验。

With 16 years of deep expertise in the clinical operations industry, Vincent Zang has previously worked at ICON, Johnson & Johnson, and Simcere Pharmaceutical. In 2019, he joined Innovent Biologics, where he has been involved in the full lifecycle clinical development of multiple drugs (including small molecule chemicals, monoclonal antibodies, bispecific antibodies, peptides, etc.), with several products successfully approved for market launch. He has accumulated extensive experience in novel drug clinical development.

邢新苗目前任职于腾盛博药医药技术（北京）有限公司，担任临床供应链负责人。她从2005年进入医药行业，先后任职于施维雅，艾尔建，拜耳研发中心，默克雪兰诺研发中心，主要从事中国以及全球临床试验供应链协调和管理工作。​

邢新苗拥有山东大学微生物学专业硕士学位，并获得美国索菲亚大学MBA学位。 此外，邢新苗持有美国项目管理协会的专业项目管理和项目集管理认证。

Fiona Xing is currently serving as the Head of Clinical Supply Chain at Brii Bioservices (Beijing) Co., Ltd. She entered the pharmaceutical industry in 2005 and worked at Servier, Allergan, Bayer R&D Center and Merck Serono R&D Center, mainly engaged in local and global clinical trial supply chain coordination and management. ​

Fiona Xing holds a master‘s degree in microbiology from Shandong University and an MBA degree from Sofia University in the United States. In addition, Fiona Xing has obtained professional Project Management (PMP) and Program Management (PgMP) certification from the American Project Management Institute.

肖申博士现任礼邦制药首席科学官，负责公司新药的临床前开发和全球药物注册，并协同首席医学官推进公司新药的临床开发工作。之前曾任海森生物医药有限公司首席医学官，思路迪医药的首席战略官和首席医学官。肖申博士曾在美国食品药物监督管理局（FDA）担任药理,毒理的非临床高级审评员负责内分泌，代谢疾病新药的非临床审评，和临床高级审评员负责心、肾、血管疾病新药的临床审评。在近二十年的 FDA工作生涯中，负责审评了数百个新药开发（IND）的各个阶段，跨度从临床前期、临床各期、及上市后的药物疗效、安全跟踪、随访；做为临床评审员和/或综合评审小组负责人负责审批了十几个新药的上市工作。其间曾在 FDA 医疗器械审评中心（CDRH），负责多个相关医疗设备的审评、审批（IDE，510k，PMA）。​

加入 FDA 之前，曾作为内科临床主治医生、博士研究助理和博士后有十多年的临床工作和实验室研究经验，包括各类普通内科疾病诊治、抗生素临床药代动力学的研究、细胞信号传导的研究等。其间除了曾获国家科技进步三等奖一项，全军科技进步二等奖一项外，还获得 FDA，美国生理协会（APS），国际肾脏病协会（ISN），日本透析和人工脏器协会的多项奖励。​

Be responsible for the setting of company's R/D product pipelines, non-clinical and clinical product development, and global regulatory affairs. Previously, he served as the Chief Medical Officer at Hasten Biopharmaceutical Co, Ltd, and the Chief Medical Officer and Chief Strategy Officer at 3D Medicines Inc for taking the full responsibilities of company’s clinical product development and global regulatory affairs.  

Before that, Dr. Xiao worked in the US FDA as a senior medical officer and was responsible for the clinical review of new drugs in the areas of Cardiovascular, renal, diabetes, obesity and some other endocrine and metabolic diseases. During his nearly 20-year career at the FDA, he reviewed several hundreds of Investigational New Drug (IND) applications across various stages, including preclinical, clinical phases, and post-marketing drug efficacy and safety tracking, and follow-up. As a clinical reviewer and/or multiple discipline team leader, he approved over a dozen of NDAs/BLAs. He also worked at the FDA’s Center for Devices and Radiological Health (CDRH), where he reviewed and approved multiple medical devices (IDE, 510K, PMA). 

Prior to FDA, as an attending physician in Nephrology in China and research fellow in US, he had over a decade of clinical practice and laboratory research experience. His experience includes diagnosing and treating a variety of general internal medicine diseases, renal diseases, conducting the clinical pharmacokinetics studies for different antibiotics, and studying cell signaling pathways. During this time, he was awarded numerous honors including the China National Scientific and Technological Third Award,  and many other awards from the FDA, the American Physiological Society (APS), the International Society of Nephrology (ISN), and the Japanese Society for Dialysis Therapy and Artificial Organs (JSDAO). 

邓晓宇先生拥有17年全球多区域医药研究开发经验，曾在多个国际领先的临床研究组织担任重要职务，包括 Labcorp、Syneos、Chiltern 和 Covance，并帮助多个亚太区企业在欧洲和美国开展医药产品临床研发工作。在新冠疫情期间，他成功领导了 Covance 亚太区的首个新冠临床研究。作为希毅医学的创始人，他带领公司帮助 80 多项生物医药项目在海外顺利落地。
邓晓宇先生毕业于哈佛大学流行病与临床试验专业，同时他也是美国项目管理协会认证项目管理专家，注册药剂师。

Xiaoyu Deng, has over 17 years of experience in global clinical research and development. Mr. Deng is a recognized expert in planning and executing clinical trials across diverse global regions. He has held key positions at leading international CROs, including Labcorp, Syneos, Chiltern, and Covance. During the COVID-19 pandemic, Mr. Deng successfully led the first COVID-19 study in the APAC region for Covance, demonstrating his ability to lead high-stakes research under tight timelines.
As the founder of MDCE, Mr. Deng has guided the company to substantial success, generating over 20 billion RMB in profits for its clients and helping more than 80 Chinese medical devices and drug products successfully land overseas.
Mr. Deng holds a Master’s degree in Public Health (Epidemiology) from Harvard University’s T.H. Chan School of Public Health. He is also a certified Project Management Professional (PMP), and a licensed pharmacist.

Dr. Claudia Hesselmann, a chemist by training, with a PhD in molecular biology. Claudia has twenty years of expertise in the early phases of drug development. Her experience includes co-founding and holding management positions in various CROs. Her extensive background and social acumen, along with her first-hand knowledge of the industry, led Claudia to co-found ARENSIA Exploratory Medicine in Düsseldorf, Germany. Her primary aim is the contribution of innovative approaches to bring about substantial acceleration to the drug development process and enable more agile patient access to novel therapeutics.